Product Description: L-NAME hydrochloride inhibits NOS with an IC50 of 70 μM. L-NAME is a precursor to NOS inhibitor L-NOARG which has an IC50 value of 1.4 μM.
Applications: Cancer-programmed cell death
Formula: C7H16ClN5O4
Citations: Adv Sci (Weinh). 2024 Apr 3:e2309002./Arterioscler Thromb Vasc Biol. 2020 Jul;40(7):1705-1721./Bioengineered. 2022 Jan;13(1):1320-1334./Biol Direct. 2024 Nov 26;19(1):121./Biomed Pharmacother. 2019 Jul;115:108934. /Biomed Pharmacother. 2023 Mar 13;161:114484./Biomed Res Int. 2021 May 15./bioRxiv. 2023 Dec 4./bioRxiv. 2023 Nov 1./BMC Nephrol. 2024 Jul 15;25(1):226./Bosn J Basic Med Sci. 2017 May 20;17(2):132-137./Cancer Metab. 2024 May 17;12(1):14./Cancer Res. 2024 Mar 19./Cardiovasc Diabetol. 2024 May 9;23(1):164./Cell Commun Signal. 2021 Mar 18;19(1):35./Evid Based Complement Alternat Med. 2020 Mar 10;2020:3524641./Exp Ther Med. 2018 Aug;16(2):1079-1086./FASEB J. 2024 Jul 31;38(14):e23844./Free Radic Biol Med. 2024 Sep 13:S0891-5849(24)00659-2./Front Cardiovasc Med. 2021 Apr 13;8:654254./Front Med. 2021 Apr 13;8:634882./Hum Gene Ther. 2022 Nov 14./Insect Mol Biol. 2024 Jan 5./Int Immunopharmacol. 2023 Dec 21:127:111313./Int Immunopharmacol. 2024 Nov 13;143(Pt 3):113617./Int J Immunopathol Pharmacol. Jan-Dec 2022;36:3946320221111117./Int J Mol Med. 2024 Aug;54(2):67./Int J Mol Sci. 2023 Mar 7./J Cardiovasc Transl Res. 2024 Jul 9./J Cell Mol Med. 2024 Apr;28(8):1-11./J Ethnopharmacol. 2022 Jun 17;115476./J Extracell Vesicles. 2023 May;12(5):e12328./JCI Insight. 2021 Sep 22;6(18):e133690./Mediat Inflamm. 2019 Oct 7;2019:6168340./Mediat Inflamm. 2020 Oct 24;2020:1649453./Microorganisms. 2024 Dec 2;12(12):2483./Microvasc Res. 2023 Mar 22;148:104531./Mol Cell Probes. 2023 Feb 2;67:101896./Nutrients. 2022, 14(23), 5025/PeerJ. 2023 May 25./Peptides. 2024 Dec 5:183:171333./Phytomedicine. 6 June 2022, 154242./Placenta. 12 November 2021./Placenta. 2021 Feb 11./Research Square Preprint. 2021 Feb./Research Square Preprint. 2022 May./Research Square Preprint. 2023 May 30./Toxicol Appl Pharmacol. 2019 Mar 1;366:83-95. /Vet Microbiol. 19 July 2022, 109514./Biomed Pharmacother. 2020 Aug;128:110240./Cell Tissue Res. 2022 Jan 29.
References: [1]Pfeiffer S, et al. Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME): requirement forbioactivation to the free acid, NG-nitro-L-arginine. Br J Pharmacol. 1996 Jul;118(6):1433-40./[2]Kopincová J, et al. L-NAME in the cardiovascular system - nitric oxide synthase activator? Pharmacol Rep. 2012;64(3):511-20./[3]Lo HC, et al. The Nitric Oxide Synthase Inhibitor NG-Nitro-L-Arginine Methyl Ester Diminishes the Immunomodulatory Effects of Parental Arginine in Rats with Subacute Peritonitis. PLoSOne. 2016 Mar 23;11(3):e0151973./[4]Luo H, et al. Effect of nitric oxide synthase inhibitor L-NAME on fear extinction in rats: a task-dependent effect. Neurosci Lett. 2014 Jun 20;572:13-8./[5]Ocsan RJ, et al. Chronic NG-nitro-l-arginine methyl ester (L-NAME) administration in C57BL/6J mice induces a sustained decrease in c-kit positive cells during development of cardiac hypertrophy. J Physiol Pharmacol. 2013 Dec;64(6):727-36./[6]V A Peotta, et al. Cardiovascular neural reflexes in L-NAME-induced hypertension in mice. Hypertension. 2001, 38, 3./[7]Xiaofei Li, et al. Fucoidan from Undaria pinnatifida prevents vascular dysfunction through PI3K/Akt/eNOS-dependent mechanisms in the l-NAME-induced hypertensive rat model. Food Funct. 2016, 7, 5.
CAS Number: 51298-62-5
Molecular Weight: 269.69
Compound Purity: 99.70
Research Area: Cancer
Solubility: H2O : 100 mg/mL (ultrasonic)
Target: NO Synthase
English
Deutsch
